Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts

British Journal of Dermatology

Volumn 176, Issue 3, 2017, Pages 643-649

  Garcia Doval I ^a,b   Hernandez M V ^c   Vanaclocha, F ^d   Sellas, A ^e   de la Cueva, P ^f   Montero, D ^g   Rodríguez, Basilio ^h   Barceló, Mireia ^h   Farietta, Sandra ^h   Montoro, María ^h   González, Ainhoa ^h   Herráez, Elena ^h   Ruíz Montesino, Ma Dolores ^h   Vargas, Carmen ^h   Pérez Pampín, Eva ^h   Ortiz, Ana Ma ^h   Tomero, Eva ^h   Sifuentes, Alberto ^h   Antón, Fred ^h   Zea, Antonio ^h   Manero Ruiz, Francisco Javier ^h   Beltrán, Chesús ^h   Giménez Úbeda, Eugenio ^h   Jimenez Zorzo, Fernando ^h   Marzo, Jesús ^h   Medrano, Marta ^h   Pecondón, Ángela ^h   Sanmartí, Raimon ^h   Cañete, Juan D ^h   Rodriguez Lozano, Carlos ^h   Naranjo, Antonio ^h   Ojeda, Soledad ^h   Hernández, Félix Francisco ^h   Erausquin, Celia ^h   Rúa, Íñigo ^h   Quevedo, Juan Carlos ^h   Manrique, Sara ^h   Ureña, Inmaculada ^h   Irigoyen, María Victoria ^h   Cano, Laura ^h   Pardo, Rosa Roselló ^h   Mateo, Isabel ^h   Garcia, Javier ^h   Enríquez, Eugenia ^h   Campos, Cristina ^h   García Borras, Juan José ^h   Nogueroles, Rosa ^h   Muñoz, Luisa ^h   Luis Valero, José ^h   Ibáñez, Andrés ^h   Carretero Hernández, Gregorio ^h   Torrado, Rosa ^h   Carrascosa Carrillo, José Manuel ^h   Ferrándiz, Carlos ^h   Rivera, Raquel ^h   Dauden, Esteban ^h   Llamas, Mar ^h   Mejías, Sagrario Galiano ^h   Gómez García, Francisco José ^h   Jiménez Puya, Rafael ^h   Herrera, Enrique ^h   Mendiola, Ma Victoria ^h   Belinchón Romero, Isabel ^h   Sánchez Carazo, José Luis ^h   López Estebaranz, José Luis ^h   Ruiz Genao, Diana ^h   Alsina, Mercè ^h   Ferran, Marta ^h   more..

^a Research Unit   (Spain)

^b UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^g Division of Pharmacoepidemiology and Pharmacovigilance   (Spain)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR; DERMATOLOGICAL AGENT; TUMOR NECROSIS FACTOR;

ADULT; ADVERSE OUTCOME; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CORTICOSTEROID THERAPY; DISEASE DURATION; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; INCIDENCE; INFECTION; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SKIN DISEASE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; MIDDLE AGED; PATIENT SAFETY; RISK FACTOR; SPAIN;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; DERMATOLOGIC AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PATIENT SAFETY; PROSPECTIVE STUDIES; PSORIASIS; RISK FACTORS; SPAIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84994846629     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14776     Document Type: Article

References (24)

1. Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008; 214:49–60.
2. Silva LC, Ortigosa LC, Benard G. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2010; 2:817–33.
3. Calamia KT. Current and future use of anti-TNF agents in the treatment of autoimmune, inflammatory disorders. Adv Exp Med Biol 2003; 528:545–9.
4. Carmona L, Descalzo MA, Ruiz-Montesinos D et al. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology (Oxford) 2011; 50:85–92.
5. Baeten D, van Hagen PM. Use of TNF blockers and other targeted therapies in rare refractory immune-mediated inflammatory diseases: evidence-based or rational? Ann Rheum Dis 2010; 69:2067–73.
6. Descalzo MA, Carmona L. [BIOBADASER 2.0: analysis and trends in 2009]. Reumatol Clin 2010; 6:240–3. (in Spanish).
7. Burmester GR, Panaccione R, Gordon KB et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013; 72:517–24.
8. Ryan C, Korman NJ, Gelfand JM et al. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol 2014; 70:146–67.
9. Medina C, Carretero G, Ferrandiz C et al. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. J Eur Acad Dermatol Venereol 2015; 29:858–64.
10. Carmona L, de la Vega M, Ranza R et al. BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries. Clin Exp Rheumatol 2014; 32(Suppl. 85):S163–7.
11. Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006; 8:R72.
12. Cobo-Ibáñez T, Descalzo MA, Loza-Santamaría E et al. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. Rheumatol Int 2014; 34:953–61.
13. Pérez-Sola MJ, Torre-Cisneros J, Pérez-Zafrilla B et al. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clin (Barc) 2011; 137:533–40.
14. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy. Rheumatology (Oxford) 2003; 42:617–21.
15. Galloway JB, Hyrich KL, Mercer LK et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011; 50:124–31.
16. Amano K. Pulmonary infections in patients with rheumatoid arthritis who have received anti-TNF therapy. Intern Med 2006; 45:991–2.
17. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013; 52:53–61.
18. Widdifield J, Bernatsky S, Paterson JM et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65:353–61.
19. Ruyssen-Witrand A, Fautrel B, Saraux A et al. Infections induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2010; 77:246–51.
20. Laskin MD, Pope JE, Krizova A et al. Are infections increased in rheumatoid arthritis (RA) prior to diagnosis? Results of a case control study of RA compared to non-inflammatory musculoskeletal disorders. Scand J Rheumatol 2005; 34:74–5.
21. Busquets N, Tomero E, Descalzo MA et al. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. Rheumatology (Oxford) 2011; 50:1999–2004.
22. Pérez-Zafrilla B, Angel Descalzo M, Carmona L. [Adverse reactions related to the administration of TNF inhibitors. Analysis of a registry of biologic therapy]. Reumatol Clin 2008; 4:90–5. (in Spanish).
23. Carrascosa JM, Vilavella M, Garcia-Doval I et al. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatol Venereol 2014; 28:907–14.
24. Dauden E, Castañeda S, Suárez C et al. Integrated approach to comorbidity in patients with psoriasis. Working Group on Psoriasis-associated Comorbidities. Actas Dermosifiliogr 2012; 103(Suppl. 1):1–64. (in Spanish).